Related Experiment Video

Updated: Apr 10, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

6.1K

Spotlight on pembrolizumab in the treatment of advanced melanoma

Thanashan Rajakulendran1, David N Adam2

  • 1Department of Medicine, Division of Dermatology, Postgraduate Medical Education, University of Toronto, Toronto, ON, Canada.

Drug Design, Development and Therapy
|June 18, 2015
PubMed

Insights

Metastatic melanoma, a deadly cancer, often resists treatment. Pembrolizumab offers a new immunotherapy approach targeting immune checkpoints, improving patient outcomes and future melanoma management.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Metastatic melanoma is an aggressive cancer with limited durable treatment options.
  • Current therapies for metastatic melanoma frequently fail to provide long-lasting responses.
  • There is a critical need for innovative therapeutic strategies in metastatic melanoma.

Purpose of the Study:

  • To discuss the recent US FDA approval of pembrolizumab for metastatic melanoma.
  • To evaluate the impact of pembrolizumab on the future management of metastatic melanoma.
  • To highlight immune checkpoint inhibitors as a therapeutic target in melanoma.

Main Methods:

  • Review of recent clinical data and regulatory approvals.
  • Discussion of the mechanism of action of immune checkpoint inhibitors.
  • Analysis of the clinical significance of pembrolizumab in metastatic melanoma.

Main Results:

  • Pembrolizumab has been approved by the US FDA for metastatic melanoma treatment.
  • Immune checkpoint modulation represents a significant advancement in cancer therapy.
  • This approval signifies a shift towards immunotherapy in melanoma management.

Conclusions:

  • Pembrolizumab represents a novel and effective therapeutic strategy for metastatic melanoma.
  • Targeting immune checkpoints is a promising approach for improving patient prognosis.
  • The approval of pembrolizumab is expected to change the landscape of melanoma treatment.
Keywords:
PD-1PD-L1immune checkpointmelanomapembrolizumab

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.6K